Comparative Pharmacology
Head-to-head clinical analysis: EMBLAVEO versus HEPARIN SODIUM 2 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMBLAVEO versus HEPARIN SODIUM 2 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
EMBLAVEO vs HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EMBLAVEO is a combination of a beta-lactam antibiotic (cefepime) and a beta-lactamase inhibitor (enmetazobactam). Enmetazobactam inhibits a broad range of beta-lactamases, including ESBLs and AmpC, thereby protecting cefepime from hydrolysis and extending its spectrum of activity against beta-lactamase-producing Gram-negative bacteria.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin), Xa, and others, thereby preventing thrombus formation and extension.
EMBLAVEO (imipenem/cilastatin/relebactam) is administered intravenously. The recommended adult dose is 1.25 g (imipenem 500 mg, cilastatin 500 mg, relebactam 250 mg) every 6 hours infused over 30 minutes.
25,000 units in 250 mL D5W (100 units/mL) continuous IV infusion at 20,000-40,000 units/24 hours; adjust based on aPTT.
None Documented
None Documented
Terminal elimination half-life is 11–12 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min).
30-150 minutes (dose-dependent, saturable); mean 60-90 min. Prolonged in hepatic/renal impairment and pulmonary embolism.
Renal excretion of unchanged drug accounts for approximately 30% of the dose; biliary/fecal elimination accounts for about 70% (60% fecal as parent drug and metabolites, 10% biliary).
Primarily renal (40-60% as unchanged drug) and reticuloendothelial system; small amount biliary/fecal. Clearance is saturable.
Category C
Category A/B
Anticoagulant
Anticoagulant